Onconova Therapeutics (ONTX) Earns Daily Media Impact Rating of 0.28

News articles about Onconova Therapeutics (NASDAQ:ONTX) have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Onconova Therapeutics earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.6077753305828 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several research analysts have weighed in on ONTX shares. ValuEngine raised shares of Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Maxim Group set a $6.00 price target on shares of Onconova Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Onconova Therapeutics in a report on Thursday, November 9th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $7.33.

Onconova Therapeutics (NASDAQ ONTX) opened at $1.76 on Friday. Onconova Therapeutics has a fifty-two week low of $1.46 and a fifty-two week high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. Onconova Therapeutics had a negative net margin of 2,855.94% and a negative return on equity of 558.97%. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.29 million. equities research analysts forecast that Onconova Therapeutics will post -2.82 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://transcriptdaily.com/2017/11/26/onconova-therapeutics-ontx-earns-daily-media-impact-rating-of-0-28.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Insider Buying and Selling by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Receive News & Ratings for Onconova Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply